Abstract
Translationally controlled tumor protein as a prognostic marker in metastatic colon cancer.
Author
person
Dragomir Svetozarov Stoyanov
Medical University of Varna, Varna, Bulgaria
info_outline
Dragomir Svetozarov Stoyanov, Mariya Penkova, Nikolay Conev, Ivan Donev
Full text
Authors
person
Dragomir Svetozarov Stoyanov
Medical University of Varna, Varna, Bulgaria
info_outline
Dragomir Svetozarov Stoyanov, Mariya Penkova, Nikolay Conev, Ivan Donev
Organizations
Medical University of Varna, Varna, Bulgaria, Department of Medical Oncology, Nadezhda Hospital, Sofia, Bulgaria
Abstract Disclosures
Research Funding
No funding received
None.
Background:
The translationally controlled tumor protein (TCTP) is a highly conserved protein present in virtually all eukaryotic organisms. TCTP is involved in a variety of normal cell functions and disease processes. Preclinical studies reveal that TCTP has anti-apoptotic properties, promotes cell growth and division, and is involved in cancer progression by promoting invasion and metastasis. Our study explores the potential value of TCTP as a prognostic marker in metastatic colon cancer.
Methods:
A retrospective analysis of 54 patients with primary metastatic colon cancer was performed. Using immunohistochemistry, TCTP levels in the primary tumor were assessed semiquantitatively via the calculation of cytoplasmic and nuclear H-score.
Results:
Cytoplasmic TCTP levels in the primary tumor had no statistically significant association with progression-free survival in first-line therapy (PFS1) and overall survival (OS) in our patient population. Patients whose primary tumors had a negative nuclear TCTP expression had significantly better clinical outcomes. The PFS1 for the negative nuclear TCTP expression group was 7.4 months (95% CI, 5.3-9.6) vs 4.5 months (95% CI, 3.4-5.6) in the group with positive nuclear expression (p = 0.023). Patients with a negative nuclear expression of TCTP had a significantly higher median OS (17.1 months; 95% CI, 13.5–20.6) compared to those with positive TCTP nuclear expression (median 11.5 months; 95% CI, 8.5-14.5) (p = 0.031). In Cox regression analyses, a positive nuclear TCTP H-score conferred a higher risk for worse PFS1 (HR 1.960; 95% CI, 1.086-3.537; p = 0.025) and OS (HR 1.882; 95% CI, 1.050-3.371; p = 0.034). The 1-year OS rate in the group with negative nuclear TCTP expression was 80.0% compared to 47.4% in patients with positive nuclear TCTP expression (p = 0.03).
Conclusions:
The present study suggests that semiquantitative H-score measurement of TCTP levels in the nuclei of tumor cells from the primary tumor is a potential prognostic marker for clinical outcomes in patients with metastatic colon cancer.
5 organizations
1 drug
1 target
Organization
Medical University of VarnaOrganization
Varna, BulgariaOrganization
Nadezhda HospitalOrganization
Sofia, BulgariaDrug
TCTPTarget
TCTP